In the latest trading session, 4.67 million Roivant Sciences Ltd (NASDAQ:ROIV) shares changed hands as the company’s beta touched 1.22. With the company’s most recent per share price at $11.07 changing hands around $0.36 or 3.36% at last look, the market valuation stands at $7.90B. ROIV’s current price is a discount, trading about -17.98% off its 52-week high of $13.06. The share price had its 52-week low at $9.76, which suggests the last value was 11.83% up since then. When we look at Roivant Sciences Ltd’s average trading volume, we note the 10-day average is 5.24 million shares, with the 3-month average coming to 4.75 million.
Analysts gave the Roivant Sciences Ltd (ROIV) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ROIV as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Roivant Sciences Ltd’s EPS for the current quarter is expected to be -0.16.
Roivant Sciences Ltd (NASDAQ:ROIV) trade information
Instantly ROIV is in green as seen in intraday trades today. With action 4.43%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -6.42%, with the 5-day performance at 4.43% in the green. However, in the 30-day time frame, Roivant Sciences Ltd (NASDAQ:ROIV) is 3.65% up. Looking at the short shares, we see there were 46.14 million shares sold at short interest cover period of 11.17 days.
The consensus price target for the stock as assigned by Wall Street analysts is 17, meaning bulls need an upside of 34.88% from its recent market value. According to analyst projections, ROIV’s forecast low is 17 with 17 as the target high. To hit the forecast high, the stock’s price needs a -53.57% plunge from its current level, while the stock would need to soar -53.57% for it to hit the projected low.
Roivant Sciences Ltd (ROIV) estimates and forecasts
Year-over-year growth is forecast to reach 13.24% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 62.17M. 4 analysts are of the opinion that Roivant Sciences Ltd’s revenue for the current quarter will be 5.19M. The company’s revenue for the corresponding quarters a year ago was 28.93M and 55.13M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 114.89%. The estimates for the next quarter sales put growth at -90.58%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.08%. The 2025 estimates are for Roivant Sciences Ltd earnings to decrease by -105.88%.
Roivant Sciences Ltd (NASDAQ:ROIV)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 27.66% of Roivant Sciences Ltd shares while 80.12% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.75%. There are 80.12% institutions holding the Roivant Sciences Ltd stock share, with SB INVESTMENT ADVISERS (UK) LTD the top institutional holder. As of 2024-06-30, the company held 9.6983% of the shares, roughly 71.36 million ROIV shares worth $754.29 million.
VIKING GLOBAL INVESTORS LP holds the second largest percentage of outstanding shares, with 9.3985% or 69.16 million shares worth $730.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. With 15.77 shares estimated at $174.29 million under it, the former controlled 2.21% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.06% of the shares, roughly 14.71 shares worth around $162.6 million.
